BACKGROUND: Problems with sexual functioning are common following therapy for breast and gynecologic @entity5 , although there are few effective treatments. OBJECTIVE: To assess the impact of ArginMax, a nutritional supplement comprised of extracts of @entity8561 , @entity9052 , gingko, and damiana, as well as multivitamins and minerals, on sexual functioning and quality of life in female @entity5 survivors. METHODS: This was a 12-week, randomized, placebo-controlled trial of eligible @entity1 who were 6 months or more from active treatment and reporting problems with sexual interest, satisfaction, and functioning after therapy. The @entity1 took 3 capsules of Arginmax or placebo twice daily. Outcome measures were the Female Sexual Function Inventory (FSFI) and the Functional Assessment of Cancer Therapy - General (FACT-G). Assessments were done at baseline, 4, 8, and 12 weeks. RESULTS: 186 @entity1 with a median age of 50 years were accrued between May 10, 2007 and March 24, 2010. 76% of the @entity1 were non-Hispanic white. Most had breast or a @entity5 (78% and 12%, respectively). At 12 weeks, there were no differences between the ArginMax group (n = 96) and placebo (n = 92) group in sexual desire, arousal, lubrication, orgasm,satisfaction or @entity158 . However, FACT-G total scores were significantly better for @entity1 who took ArginMax compared with those who took placebo (least squares [LS] means, 87.5 vs 82.9, respectively; P = .009). The Fact-G subscales that were most affected were Physical (25.37 vs. 23.51, P = .001) and Functional Well-Being (22.46 vs. 20.72, P = .007). @entity137 were similar for both groups. LIMITATIONS: Study results are limited by a lack of data on the @entity1 ' psychological and physical symptoms and sexual partner variables. CONCLUSIONS: ArginMax had no significant impact on sexual functioning, but @entity1 quality of life was significantly better at 12 weeks in @entity1 who received ArginMax.

Effect of ArginMax on sexual functioning and quality of life among female XXXX survivors: results of the WFU CCOP Research Base Protocol 97106.

@entity1 :: ('9606', 'Species') :: ['participants', 'patients', 'patient'] @entity8561 :: ('D001120', 'Chemical') :: ['L-arginine'] @entity137 :: ('MESH:D064420', 'Disease') :: ['Toxicities'] @entity5 :: ('MESH:D009369', 'Disease') :: ['gynecologic cancer', 'cancers', 'cancer'] @entity158 :: ('MESH:D010146', 'Disease') :: ['pain'] @entity9052 :: ('4054', 'Species') :: ['ginseng']
@entity5 :: (MESH:D009369,Disease) :: ['cancer']
